UnicoCell Biomed Co., Ltd. (6794.TW)
Taiwan · TWD · Healthcare · Biotechnology
NT$68.80 (+0.29%) as of
Key statistics
- Market cap
- 4.38B
- EPS (TTM)
- -1.65
- Dividend yield
- 0.00%
- 52-week range
- 65.60 – 93.20
- Beta
- -0.23
- Revenue (TTM)
- 22.46M
- Profit margin
- 0.00%
- Volume
- 38.08k
About UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products. UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.